EUROPEAN RENAL ASSOCIATION - EUROPEAN DIALYSIS AND TRANSPLANT ASSOCIATION
Services
How to use the platform
Build a poster
MANAGE ORDERS
FAQs
Contact
HOMEPAGE
Virtual Poster Gallery
PrintingOnline for Collection on-site
Accredited Training
DOI - Digital Object Identifier
What is PosterSessionOnline?
How to send your poster
How to visit the Virtual Poster Gallery
How to build a poster
How to reduce a poster to less than 2 Mb
PosterSessionOnline Image Editor
How to build a poster with our templates
How to work with a template
Templates and instructions
Discussion forum -
49th ERA-EDTA Congress
Topic -
Mineral and bone disease - CKD 5D
If you are already registered in PosterSessionOnline, enter your e-mail and click on LOGIN. Otherwise click on REGISTER.
Poster:
231
Visits:
633
Title:
Uremia suppresses immune signal-induced CYP27B1 expression in human monocytes, while increasing background expression
Authors:
Liesbeth Viaene ,
Centre:
UZ Gasthuisberg Nephrology and clinical and experimental endocrinology
You must be registered to reply or comment.
UREMIA SUPPRESSES IMMUNE SIGNAL-INDUCED CYP27B1 EXPRESSION IN HUMAN MONOCYTES, WHILE INCREASING BACKGROUND EXPRESSION
Liesbeth Viaene
Thread initiator
Subspeciality
Reg:
5/10/2012 4:30:00 PM
Comment# 1
I invite healthcare professionals to open debate around the issues raised in my poster, both those relating to research and to clinical practice.
Comment added on 5/10/2012 4:31:00 PM
You must be registered to reply or comment.
Most viewed poster for this congress
Poster:
424
Visits:
2636
Title:
Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Glomerulonephritides: an Immunohystochemical expression analysis
Authors:
Giuseppe Coppolino ,
Centre:
Chair of Nephrology, University Magna Graecia of Catanzaro, Catanzaro, Italy
Poster most viewed in this topic
Poster:
558
Visits:
1052
Title:
CINACALCET VS. PARICALCITOL IN HEMODIALYSIS PATIENTS
Authors:
NICKOS KAPERONIS ,
Centre:
RED CROSS HOSPITAL, ATHENS
View Poster Gallery
Back to congress home
Other Congresses
About us
|
Terms and Conditions
|
Special Access